Short answer
Merck & Co. (MRK) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Third-quarter 2026 earnings announced in Merck’s October 29, 2026 press release.
Merck & Co. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter 2026 earnings announced in Merck’s October 29, 2026 press release
- Supplemental financial information provided in Exhibit 99.2 for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $18.1B, up 5%, led by KEYTRUDA $8.6B and WINREVAIR $694M, up 93%
- GAAP EPS $2.04, down 12%; non-GAAP EPS $2.49, down 3%, including $0.12 SciBrunch charge
- Gross margin fell to 72.9% from 77.7%, reflecting higher amortization, restructuring and production costs
- 2026 sales outlook raised to $66.8B-$67.3B; non-GAAP EPS raised to $2.77-$2.82
- Sac-TMT FDA priority review and melanoma vaccine data strengthen pipeline, while I-DXd withdrawal removes an oncology opportunity
Item EX-99.2 · Exhibit EX-99.2
- Q3 sales $18,085M, up 5%; pharmaceutical sales $16,268M, up 4%, while Animal Health rose 4% to $1,676M
- Keytruda sales fell 5% to $7,771M, offset by Keytruda Qlex $830M and Winrevair growth of 93% to $694M
- Q3 GAAP net income $5,067M, down from $5,787M; diluted EPS $2.04 versus $2.32
- September YTD GAAP net loss $513M, driven by $26,871M of R&D expense and $1,900M of acquisition-related costs
- September YTD non-GAAP EPS $6.93 versus GAAP loss per share of $0.21, highlighting substantial acquisition and restructuring adjustments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Merck & Co. 8-K filings
Get the next MRK 8-K as it lands
Follow MRK for push alerts, or ask the research agent what this filing means.